Pinealon

Peptide bioregulator is the term used by the Khavinson school at the St Petersburg Institute of Bioregulation and Gerontology for a family of very short peptides, typically two to four residues, hypothesised to regulate gene expression in the tissue class from which the original peptide extracts were derived. Pinealon, the Glu-Asp-Arg tripeptide, is the member associated with brain tissue. The term describes a research hypothesis from largely one group, not an established pharmacological class, and that distinction is worth keeping in view when reading the surrounding literature.

The mechanism on offer in the published work is epigenetic and explicitly proposed rather than proven. A 2021 paper from Khavinson and colleagues (PubMed 33396470) describes a possible mechanism by which the EDR tripeptide could regulate gene expression and protein synthesis in neuronal models, presented by the authors as a candidate route to neuroprotection. A 2024 in-vitro study (PubMed 39518916) reported that EDR reduced markers of oxidative DNA damage in induced neurons derived from elderly donor fibroblasts. Both are preclinical findings from the same research school and neither establishes a confirmed mechanism.

No randomised controlled trial of Pinealon has been published. The indexed literature on the EDR peptide is small, comes largely from a single research group, and consists mostly of in-vitro experiments and small animal studies, without independent replication at scale. Any claim of established effects in humans is not supported by the published record, and this page does not make one. The compound is supplied for laboratory research precisely because these questions remain open.

Pinealon may be purchased in the UK as a research chemical for in vitro laboratory use only. It is not an approved or licensed medicine in the UK and is not supplied for human consumption, veterinary use, or any therapeutic purpose. Purchasers must be 18 or over and confirm research-only use at checkout.

Each vial contains 10mg of Pinealon (Glu-Asp-Arg) supplied as a white lyophilised powder. Batch UKPL-608 is stated at 98.8% purity by RP-HPLC on a supplier-reported certificate of analysis, published on the product page. Independent verification is pending. Keep lyophilised vials at -20°C protected from light and moisture, reconstitute with bacteriostatic water run gently down the inner glass wall, and hold the reconstituted solution at 2-8°C.

UK Peptide Lab sells Pinealon 10mg from UK stock, batch UKPL-608. Orders placed before 3pm UK time on a working day are dispatched the same day, and UK Royal Mail Tracked delivery is free over £59.

Not yet. Batch UKPL-608 carries a supplier-reported certificate stating 98.8% purity by RP-HPLC, and independent verification is pending. The full report is published on the product page, not supplied on request. The expected mass for Glu-Asp-Arg is 418.4 g/mol.

Pinealon is used to test the Khavinson peptide bioregulator hypothesis. Typical work covers neuronal culture models of ageing and oxidative stress, and assays of gene expression and protein synthesis. Replication studies are useful too, because the literature is small and mostly from one group.